Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I–IIIB breast cancer receiving chemotherapy

Abstract

Purpose Initial dose of chemotherapy is planned based on body surface area, which does not take body composition into account. We studied the association between fat mass (kg and relative to total body weight) as well as lean mass (kg and relative to total body weight) and toxicity-induced modifications of treatment in breast cancer patients receiving chemotherapy. Methods In an observational study among 172 breast cancer patients (stage I–IIIB) in the Netherlands, we assessed body composition using dual-energy X-ray scans. Information on toxicity-induced modifications of treatment, defined as dose reductions, cycle delays, regimen switches, or premature termination of chemotherapy, was abstracted from medical records. Adjusted hazard ratios and 95% confidence intervals (95% CI) were calculated to assess associations between body composition and the risk of toxicity-induced modifications of treatment. Results In total, 95 out of 172 (55%) patients experienced toxicity-induced modifications of treatment. Higher absolute and relative fat mass were associated with higher risk of these modifications (HR 1.14 per 5 kg; 95% CI 1.04–1.25 and HR 1.21 per 5%; 95% CI 1.05–1.38, respectively). A higher relative lean mass was associated with a lower risk of modifications (HR 0.83 per 5%; 95% CI 0.72–0.96). There was no association between absolute lean mass and risk of toxicity-induced modifications of treatment. Conclusions A higher absolute and a higher relative fat mass was associated with an increased risk of toxicity-induced modifications of treatment. Absolute lean mass was not associated with risk of these treatment modifications, while higher relative lean mass associated with lower risk of modifications. These data suggest that total fat mass importantly determines the risk of toxicities during chemotherapy in breast cancer patients. Electronic supplementary material The online version of this article (10.1007/s10549-018-5014-5) contains supplementary material, which is available to authorized users.

The relationship between computed tomography derived skeletal muscle index, psoas muscle index and clinical outcomes in patients with operable colorectal cancer

“…Both left and right psoas muscle areas were outlined as shown in Fig. 2 and added for total psoas muscle area [21] and this was normalized by height squared for PMI. Whole L3 Skeletal muscles i.e.…”

Changes in body composition during and after adjuvant or neo-adjuvant chemotherapy in women with breast cancer stage I–IIIB compared with changes over a similar timeframe in women without cancer

“…Changes in body weight and/or body composition are of potential clinical relevance as it has been suggested that increases in weight, increases in fat mass and/or decreases in lean mass are associated with cancer recurrence and mortality [3,11], although data on this are not fully consistent [12][13][14][15]. Moreover, recent studies suggest that body composition is importantly associated with toxicity-induced modifications of treatment [16][17][18], which warrants further research into how body composition changes over time during chemotherapy.…”

Management of diet in gastrointestinal cancer

“…Studies of the impact of sarcopenia in different cancer diagnoses have indicated varying results. Some have indicated that the loss of muscle mass influences tolerance to SACT with low muscle mass, in people with normal or increased body weight, increases the risk of toxicity often resulting in dose reduction of drugs (28,29) . Other studies have suggested that myosteatosis, fatty infiltration of muscle, defined as attenuated mean skeletal muscle Hounsfield units observed on computed tomography scanning, has a greater bearing on survival rather than reduced muscle mass alone (26) .…”